BDMD
BEARISH
$1.03
Live
Baird Medical Investment Holdings Limited · NASDAQ
$0.99
52W Range
$8.29
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$37.83M
P/E
N/A
ROE
-8.0%
Profit margin
-10.0%
Debt/Equity
0.63
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
92%
The Advanced Deterministic Scorecard reveals a critically weak financial profile with a Piotroski F-Score of just 3/9, indicating poor financial health. Despite a seemingly reasonable Price/Book of 0.77 and a strong Gross Margin of 86.94%, the company is deeply unprofitable with negative operating and net margins, collapsing revenue, and no analyst coverage. The complete absence of Altman Z-Score and intrinsic value calculations, combined with a 5-year return of -89.3%, signals severe distress. Technical indicators and insider sentiment are also weak, reinforcing a high-risk outlook.
Key Strengths
High gross margin of 86.94% suggests strong pricing power or low production costs in core operations
Current ratio of 1.71 indicates short-term liquidity is manageable
Quick ratio of 1.22 shows the company can meet immediate obligations without relying on inventory
Debt/Equity of 0.63 is below sector average of 2.71, suggesting conservative leverage
Price/Book of 0.77 implies potential undervaluation relative to book value
Key Risks
Piotroski F-Score of 3/9 indicates severe financial weakness and high risk of continued underperformance
Operating margin of -131.30% reflects deep operational inefficiencies or unsustainable cost structure
Revenue growth YoY of -39.40% shows rapid top-line contraction
No Altman Z-Score available, increasing uncertainty about bankruptcy risk
Market cap of $0.04B and lack of analyst coverage suggest minimal institutional interest and high volatility
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
20
Weak
58
12
10
18
0
AI Verdict
Highly distressed with minimal investor confidence
Key drivers: Low Piotroski F-Score, Negative profitability metrics, Collapse in revenue growth, Lack of analyst coverage, Severe long-term price underperformance
Confidence
90%
Value
58/100
Ref P/E, PEG, Graham Number
Positives
- Price/Book of 0.77 below 1.0 suggests possible undervaluation
- Price/Sales of 1.19 is moderate for a medical device firm
Watchpoints
- No P/E, Forward P/E, or PEG due to unprofitability
- No Graham Number or intrinsic value estimate available
Future
12/100
Ref Growth rates
Positives
No standout positives identified.
Watchpoints
- Revenue growth YoY at -39.40%
- No earnings growth data available, likely negative
- No analyst target prices or growth estimates
Past
10/100
Ref Historical trends
Positives
No standout positives identified.
Watchpoints
- 5Y price change: -89.3%
- 3Y price change: -90.0%
- 1Y price change: -87.4%
- 6M price change: -49.5%
Health
18/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current and quick ratios above 1.0 indicate short-term solvency
Watchpoints
- Piotroski F-Score of 3/9 indicates weak financial health
- ROE of -8.03% and ROA of -0.20% show poor returns
- Operating margin of -131.30% is catastrophic
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- Dividend Strength: 0/100
- No dividend yield or payout history
- No indication of future dividend plans
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$1.03
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for BDMD and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
BDMD
Baird Medical Investment Holdings Limited
Primary
|
-89.3% | -90.0% | -87.4% | -49.5% | -26.9% | -10.4% |
|
ATRA
Atara Biotherapeutics, Inc.
Peer
|
-98.9% | -95.6% | -24.7% | -54.9% | -70.3% | +15.0% |
|
NMTC
NeuroOne Medical Technologies Corporation
Peer
|
-88.5% | -57.8% | +32.2% | -19.5% | +1.4% | -12.1% |
|
RADX
Radiopharm Theranostics Limited
Peer
|
-74.1% | -74.1% | +6.5% | -35.6% | -2.5% | -1.7% |
|
RMTI
Rockwell Medical, Inc.
Peer
|
-90.9% | -57.7% | -11.7% | -22.2% | -11.7% | 0.0% |
BDM
Baird Medical Investment Holdings Limited
Primary
5Y
-89.3%
3Y
-90.0%
1Y
-87.4%
6M
-49.5%
1M
-26.9%
1W
-10.4%
ATR
Atara Biotherapeutics, Inc.
Peer
5Y
-98.9%
3Y
-95.6%
1Y
-24.7%
6M
-54.9%
1M
-70.3%
1W
+15.0%
NMT
NeuroOne Medical Technologies Corporation
Peer
5Y
-88.5%
3Y
-57.8%
1Y
+32.2%
6M
-19.5%
1M
+1.4%
1W
-12.1%
RAD
Radiopharm Theranostics Limited
Peer
5Y
-74.1%
3Y
-74.1%
1Y
+6.5%
6M
-35.6%
1M
-2.5%
1W
-1.7%
RMT
Rockwell Medical, Inc.
Peer
5Y
-90.9%
3Y
-57.7%
1Y
-11.7%
6M
-22.2%
1M
-11.7%
1W
0.0%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
N/A
PEG Ratio
N/A
P/B Ratio
0.77
P/S Ratio
1.19
EV/Revenue
1.49
EV/EBITDA
51.6
Market Cap
$37.83M
Profitability
Profit margins and return metrics
Profit Margin
-9.95%
Operating Margin
-131.3%
Gross Margin
86.94%
ROE
-8.03%
ROA
-0.2%
Growth
Revenue and earnings growth rates
Revenue Growth
-39.4%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.63
Moderate
Current Ratio
1.71
Good
Quick Ratio
1.22
Good
Cash/Share
$0.09
Healthcare Sector Comparison
Comparing BDMD against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-8.03%
This Stock
vs
-88.14%
Sector Avg
-90.9%
(Below Avg)
Profit Margin
-9.95%
This Stock
vs
-16.28%
Sector Avg
-38.9%
(Weaker)
Debt to Equity
0.63
This Stock
vs
2.66
Sector Avg
-76.2%
(Less Debt)
Revenue Growth
-39.4%
This Stock
vs
124.04%
Sector Avg
-131.8%
(Slower)
Current Ratio
1.71
This Stock
vs
4.47
Sector Avg
-61.7%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
BDMD
Baird Medical Investment...
|
BEARISH | $37.83M | - | -8.0% | -10.0% | $1.03 | |
|
ATRA
Atara Biotherapeutics, Inc.
|
BEARISH | $37.64M | 1.83 | -% | 15.4% | $5.22 | Compare |
|
NMTC
NeuroOne Medical...
|
BEARISH | $37.01M | - | -146.3% | -58.3% | $0.73 | Compare |
|
RADX
Radiopharm Theranostics Limited
|
BEARISH | $36.1M | - | -92.1% | -286.2% | $4.58 | Compare |
|
RMTI
Rockwell Medical, Inc.
|
BEARISH | $36.0M | - | -15.3% | -7.7% | $0.91 | Compare |
BDMD
Baird Medical...
BEARISH
Mkt Cap
$38M
P/E
-
ROE
-8.0%
Price
$1.03
Past News Coverage
Recent headlines mentioning BDMD from our newsroom.
Newest → oldest
No matching news yet.